Names and Identifiers

• • Litorin (peptide) (9CI)
  • Litorin
  • GLP-GLN-TRP-ALA-VAL-GLY-HIS-PHE-MET-NH2
  • 2-De-L-Val-3-de-L-Pro-ranatensin
  • 5-Oxo-L-Pro-L-Gln-L-Trp-L-Ala-L-Val-Gly-L-His-L-Phe-L-Met-NH2
  • Efonidipine hydrochloride monoethanolate
  • GLP-GLN-TRP-ALA-VAL-GLY-HIS-PHE-MET-NH2: GLP-QWAVGHFM-NH2
  • M.W. 1084.47 C51H68N14O11S
  • pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2
  • pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2,Pituitary adenylate cyclase activating fragment 21-38
  • Pituitary adenylate cyclase activating fragment 21-38
  • PYR-GLN-TRP-ALA-VAL-GLY-HIS-PHE-MET-NH2
  • 55749-97-8
  • (S)-N1-((5S,8S,11S,17S,20S,23S)-11-((1H-imidazol-5-yl)methyl)-8-benzyl-5-carbamoyl-24-(1H-indol-3-yl)-17-isopropyl-20-methyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazatetracosan-23-yl)-2-((S)-5-oxopyrrolidine-2-carboxamido)pentanediamide
  • AKOS040744635
  • Litorin (trifluoroacetate salt)
  • HY-103281
  • Litorine
  • Litorin (peptide)
  • MS-31944
  • Ranatesin, 2-de-L-valine-3-de-L-proline-
  • DTXSID40204308
  • AKOS024456853
  • CS-0027101
  • DTXCID00126799
  • DA-65012
  • G12440
  • +expand
• • MDL： MFCD00167519
  • Inchi： 1S/C51H68N14O11S/c1-27(2)43(51(76)56-25-42(68)60-39(22-31-24-54-26-57-31)50(75)63-37(20-29-10-6-5-7-11-29)49(74)61-34(44(53)69)18-19-77-4)65-45(70)28(3)58-48(73)38(21-30-23-55-33-13-9-8-12-32(30)33)64-47(72)36(14-16-40(52)66)62-46(71)35-15-17-41(67)59-35/h5-13,23-24,26-28,34-39,43,55H,14-22,25H2,1-4H3,(H2,52,66)(H2,53,69)(H,54,57)(H,56,76)(H,58,73)(H,59,67)(H,60,68)(H,61,74)(H,62,71)(H,63,75)(H,64,72)(H,65,70)/t28-,34-,35-,36-,37-,38-,39-,43-/m0/s1
  • InChI Key： OHCNRADJYUSTIV-FPNHNIPFSA-N
  • SMILES： S(C)CC[C@@H](C(N)=O)NC([C@H](CC1C=CC=CC=1)NC([C@H](CC1=CN=CN1)NC(CNC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CNC2C=CC=CC1=2)NC([C@H](CCC(N)=O)NC([C@@H]1CCC(N1)=O)=O)=O)=O)=O)=O)=O)=O)=O

Computed Properties

Experimental Properties